医療用医薬品 : タケキャブ (タケキャブ錠10mg 他) - KEGG
2024年10月23日 · 効能または効果. 胃潰瘍 、 十二指腸潰瘍 、 逆流性食道炎 、低用量アスピリン投与時における 胃潰瘍又は十二指腸潰瘍 の再発抑制、非ステロイド性抗炎症薬投与時における 胃潰瘍又は十二指腸潰瘍 の再発抑制. 下記における ヘリコバクター・ピロリの除菌の補助. 胃潰瘍 、 十二指腸潰瘍 、胃MALTリンパ腫、特発性血小板減少性紫斑病、早期胃癌に対する内視鏡的治療後胃、 ヘリコバクター・ピロリ感染胃炎. 5. 効能または効果に関連する注意. ＜低用 …
Takecab Tablets 10mg : Takeda Pharmaceutical Company …
PRESCRIPTION. “Takecab Tablets 10mg” is a prescription medicine (Rx) in Japan. 2. IMPORT (SUPPORTING) DOCUMENTS. Certificate of Origin (CoO), Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) of “Takecab Tablets 10mg” are available. *PIL and SmPC are written in Japanese.
TAKECAB® Now Available for the Treatment of Acid-related Diseases …
2015年2月26日 · TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H +,K +-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal ...
New Drug Application for Oral Disintegrated Tablet Formulation …
2021年3月22日 · TAKECAB OD tablets are suitable for patients with impaired swallowing, including elderly patients, and the increase in treatment options can also be expected to improve medication adherence. Based on a domestic co-promotion agreement concluded in 2014, Takeda will manufacture and sell TAKECAB OD tablets, with informational activities conducted ...
Vonoprazan: first global approval - PubMed
Vonoprazan (Takecab (®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, d ….
Vonoprazan: First Global Approval | Drugs - Springer
2015年3月6日 · Vonoprazan (Takecab ®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro ...
Takecab Tablets 20mg [agents for killing Helicobacter
2020年1月10日 · ACTIVE INGREDIENT: Vonoprazan fumarate. DOSAGE FORM: faint red oval tablet, major axis: 11.2 mm, minor axis: 6.2. mm, thickness: 3.9 mm. IMPRINT OR PRINT ON WRAPPING: (Face)タケキャブ 20mg, (Back)タケキャブ 20. EFFECTS OF THIS MEDICINE. This medicine inhibits the proton pump in a potassium ion-competitive.
Takecab Tablets 10mg [agents for killing Helicobacter pylori]
In general, for adults, take 2 tablets (20 mg of vonoprazan) at a time, twice a day for 7 days. Take this medicine together with two antibacterial medicines. Strictly follow the instructions. If you miss a dose, take the missed dose as soon as possible.
Takecab OD Tablets 20mg [agents for digestive organ]
2023年1月7日 · ACTIVE INGREDIENT: Vonoprazan fumarate. DOSAGE FORM:
Kusuri-no-Shiori(Drug Information Sheet) - くすりの適正使用 ...
Suppression of recurrence of gastric/duodenal ulcers associated with low-dose aspirin or non-steroidal anti-inflammatory drug therapy: In general, for adults, take 1 tablet (10 mg of vonoprazan) at a time, once a day. In any case, strictly follow the instructions. If you miss a dose, take the missed dose as soon as possible.